Chad Messer Analyst PerformanceSenior Life Science Equity Analyst at Lake Street CapitalChad Messer is a stock analyst at Lake Street Capital focused in the medical sector, covering 36 publicly traded companies. Over the past year, Chad Messer has issued 9 stock ratings, including and buy recommendations. While full access to Chad Messer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Chad Messer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings159 Last 10 YearsBuy Recommendations97.47% 154 Buy RatingsCompanies Covered36 Unique Companies Ratings Distribution158RatingsDistribution of strong buy, buy, hold, and sell ratings by Chad Messer.RatingPercentageCount Strong Buy4.4%7 ratings Buy93.0%147 ratings Hold2.5%4 ratings Sell0.0%0 ratingsOut of 158 total stock ratings issued by Chad Messer at Lake Street Capital, the majority (93.0%) have been Buy recommendations, followed by 4.4% Strong Buy and 2.5% Hold.Best & Worst CallsBest Call0000.0%VCELMar 2017Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TLOGMar 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ91.7% of companies on NASDAQ33 companiesOTCMKTS5.6% of companies on OTCMKTS2 companiesNYSE2.8% of companies on NYSE1 companyChad Messer, an analyst at Lake Street Capital, currently covers 36 companies listed on NASDAQ, OTCMKTS and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical35 companies97.2%Miscellaneous1 company2.8%Chad Messer of Lake Street Capital specializes in stock coverage within the Medical sector, with additional focus on companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE17 companies47.2%PHARMACEUTICAL PREPARATIONS9 companies25.0%MED - DRUGS4 companies11.1%BIOTECHNOLOGY2 companies5.6%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC2 companies5.6%Miscellaneous1 company2.8%SURGICAL APPLIANCES & SUPPLIES1 company2.8% Chad Messer's Ratings History at Lake Street Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMNPRMonopar Therapeutics9/23/2025Initiated Coverage$63.66$106.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics9/23/2025Initiated Coverage$73.04$106.00Buy$0.0000.00% ROIBOLTBolt Biotherapeutics8/15/2025Boost Price Target$5.40$75.00Buy$0.0000.00% ROIONCYOncolytics Biotech8/13/2025Initiated Coverage$0.86$7.00Buy$0.0000.00% ROICOYACoya Therapeutics7/9/2025Initiated Coverage$6.11$16.00Buy$0.0000.00% ROIBOLTBolt Biotherapeutics5/20/2025Initiated Coverage$6.52$80.00Buy$0.0000.00% ROIIMNMImmunome4/2/2025Initiated Coverage$6.26$23.00Buy$0.0000.00% ROIOSTXOS Therapies4/2/2025Initiated Coverage$1.33$19.00Buy$0.0000.00% ROILTRNLantern Pharma4/2/2025Initiated Coverage$3.31$25.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
